GO:0045518 interleukin-22 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045518 interleukin-22 receptor binding is a molecular function describing the binding of a ligand to an interleukin-22 receptor.
• The primary ligand is the cytokine IL-22, which engages the heterodimeric receptor IL-22R1/IL-10R2 to initiate signaling.
• IL-22 binding protein (IL-22BP) is a soluble decoy receptor that competes with membrane-bound IL-22R1 for IL-22, thereby regulating the function.
• This binding event is central to epithelial barrier immunity, tissue repair, and host defense, and is implicated in inflammatory diseases such as uveitis, periodontitis, and lung injury.
• Altered expression of IL-22 receptor 1 on blood hematopoietic cells has been observed in SARS-CoV-2 infection, linking this function to viral pathogenesis.
• Studying GO:0045518 requires methods such as surface plasmon resonance, co-immunoprecipitation, and CRISPR-based knockouts of IL22RA1 or IL22.
Description
Interleukin-22 receptor binding (GO:0045518) is a molecular function defined as the binding to an interleukin-22 receptor. This event is the first step in the cellular response to the cytokine interleukin-22 (IL-22), a member of the IL-10 family that plays critical roles in mucosal immunity, tissue regeneration, and inflammation. The binding of IL-22 to its receptor complex triggers downstream signaling pathways that regulate gene expression, cell proliferation, and survival, making it a key node in both protective and pathological immune responses. Researchers study this function to understand how IL-22 exerts its pleiotropic effects and to develop therapeutic strategies for diseases ranging from autoimmune conditions to infectious diseases. The interaction is tightly regulated by a soluble decoy receptor, IL-22 binding protein (IL-22BP), which modulates the availability of free IL-22 and thus the extent of receptor binding. This article provides a comprehensive overview of the molecular mechanism, key genes, disease associations, and research methodologies for studying interleukin-22 receptor binding.
interleukin-22 receptor binding At A Glance
| GO ID | GO:0045518 |
|---|---|
| GO term | interleukin-22 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-22, interleukin-22 receptor ligand |
| Definition | Binding to an interleukin-22 receptor. |
| Major function | Mediates the initial interaction between IL-22 and its receptor complex, leading to signal transduction. |
| Primary ligand | Interleukin-22 (IL-22) |
| Receptor components | IL-22R1 (IL22RA1) and IL-10R2 (IL10RB) |
| Regulator | IL-22 binding protein (IL-22BP, encoded by IL22BP) acts as a decoy receptor. |
What Is GO:0045518?
According to the Gene Ontology, GO:0045518 interleukin-22 receptor binding is a molecular function that describes the binding of a molecule to an interleukin-22 receptor. In practice, this term is used to annotate the interaction between the cytokine IL-22 and its specific cell-surface receptor complex, primarily composed of IL-22R1 (encoded by IL22RA1) and IL-10R2 (encoded by IL10RB). The binding is non-covalent and highly specific, initiating a signaling cascade that leads to the activation of transcription factors such as STAT3. This function is distinct from other cytokine-receptor interactions due to the unique structural features of IL-22 and its receptor, which have been characterized by crystallographic and biochemical studies.
Why Is interleukin-22 receptor binding Important in Cell Biology?
Interleukin-22 receptor binding is a critical molecular event that governs the biological activities of IL-22, a cytokine at the interface of innate and adaptive immunity. This binding event determines the specificity and magnitude of IL-22 signaling, which is essential for epithelial cell survival, antimicrobial peptide production, and tissue repair. Dysregulation of this interaction is associated with a range of human diseases, including autoimmune uveitis, periodontitis, pneumonia, and lung injury. Understanding the molecular details of IL-22 receptor binding provides insights into disease pathogenesis and offers opportunities for therapeutic intervention, such as blocking or enhancing this interaction with biologics or small molecules.
• Initiates IL-22 signaling, which is crucial for mucosal host defense and epithelial regeneration.
• Regulates inflammatory responses in autoimmune diseases such as experimental autoimmune uveitis.
• Modulates airway hyperresponsiveness and allergic inflammation through IL-22BP.
• Plays a role in periodontal tissue homeostasis and disease progression.
• Influences the Th1/Th17 axis, linking IL-22 to T cell-mediated immunity.
• Constrains IL-22 activity during bacterial pneumonia, affecting oxidative phosphorylation genes.
• Controls IL-22-driven lung injury and fibrosis in bleomycin-induced models.
• Altered IL-22 receptor expression on hematopoietic cells in SARS-CoV-2 infection suggests a role in viral pathogenesis.
• Provides a target for therapeutic modulation in inflammatory and infectious diseases.
• Serves as a model for studying cytokine-receptor specificity and decoy receptor regulation.
Molecular Mechanism of interleukin-22 receptor binding
Ligand Recognition and Binding Interface
In simple terms: IL-22 binds to its receptor like a key fitting into a lock, with specific contact points.
The binding of IL-22 to its receptor is mediated by specific structural determinants. IL-22 is a helical cytokine that shares structural homology with IL-10, but its receptor-binding interface is distinct. The interaction primarily involves the extracellular domains of IL-22R1 and IL-10R2, with IL-22 first binding to IL-22R1 with high affinity, followed by recruitment of IL-10R2 to form a functional signaling complex. This sequential binding ensures specificity and allows for regulation by soluble decoy receptors.
Receptor Complex Assembly and Stoichiometry
In simple terms: The receptor is made of two different proteins that come together when IL-22 binds.
The functional IL-22 receptor is a heterodimer composed of IL-22R1 and IL-10R2. IL-22R1 is the specific subunit that confers ligand specificity, while IL-10R2 is a shared subunit also used by other cytokines such as IL-10 and IL-26. The assembly of this complex is a dynamic process that occurs at the cell membrane, and the stoichiometry of the ligand-receptor interaction has been characterized biochemically. The formation of this complex is essential for downstream signaling, as neither subunit alone can transmit the signal.
Regulation by Soluble Decoy Receptor IL-22BP
In simple terms: A soluble protein called IL-22BP acts as a decoy that soaks up IL-22, preventing it from binding to the cell surface receptor.
IL-22 binding protein (IL-22BP) is a soluble, secreted protein that binds IL-22 with high affinity and competes with the membrane-bound IL-22R1 for ligand binding. By sequestering IL-22, IL-22BP prevents the formation of the IL-22/IL-22R1/IL-10R2 complex and inhibits downstream signaling. This regulation is critical for limiting excessive IL-22 activity during inflammation and infection, as demonstrated in models of pneumococcal pneumonia and bleomycin-induced lung injury. The balance between IL-22 and IL-22BP determines the net signaling output and is a key regulatory node.
Temporal and Spatial Expression of Receptor Components
In simple terms: The receptor and its binding protein are expressed at different times and places, affecting when and where IL-22 can act.
The expression of IL-22, IL-22R1, and IL-22BP is dynamically regulated in a tissue- and context-specific manner. For example, during experimental periodontitis, the temporal expression of these components changes over the course of disease, influencing the progression of inflammation and tissue destruction. Similarly, in SARS-CoV-2 infection, distinct expression patterns of IL-22R1 on blood hematopoietic cells have been observed, suggesting a role in the immune response to the virus. These expression patterns dictate the availability of binding partners and thus the functional outcome of IL-22 receptor binding.
Key Genes Involved in GO:0045518 interleukin-22 receptor binding
The following genes and proteins are directly involved in or regulate interleukin-22 receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL22 | Encodes the cytokine IL-22, the primary ligand for the receptor. | Central to studying binding specificity and downstream signaling. |
| IL22RA1 | Encodes the IL-22 receptor subunit alpha 1, which binds IL-22 with high affinity. | Key target for knockout and point mutation studies to dissect binding interfaces. |
| IL10RB | Encodes the IL-10 receptor subunit beta, a shared component of the IL-22 receptor complex. | Required for functional signaling; studied in complex assembly. |
| IL22BP | Encodes the soluble decoy receptor IL-22BP that binds and neutralizes IL-22. | Regulates IL-22 bioavailability; knockout models show enhanced IL-22 activity. |
| STAT3 | Transcription factor activated downstream of IL-22 receptor binding. | Readout of IL-22 signaling; often assessed by phosphorylation. |
| JAK1 | Janus kinase associated with IL-22R1 that phosphorylates STAT3. | Involved in signal transduction; can be targeted in studies. |
| TYK2 | Janus kinase associated with IL-10R2 that contributes to signaling. | Part of the receptor complex; studied in knockout cells. |
| SOCS3 | Suppressor of cytokine signaling 3, a negative feedback regulator of IL-22 signaling. | Modulates the duration and intensity of IL-22 responses. |
| REG3A | Antimicrobial peptide induced by IL-22 in epithelial cells. | Biomarker of IL-22 receptor binding activity. |
| MUC1 | Mucin 1, a target gene of IL-22 involved in barrier function. | Used to assess functional outcomes of IL-22 binding. |
| CXCL10 | Chemokine induced by IL-22 in some contexts. | Marker of IL-22-mediated inflammation. |
| IL17A | Cytokine that interacts with IL-22 in Th17 responses. | Studied in conjunction with IL-22 in autoimmune models. |
| IFNG | Interferon gamma, which influences Th1/Th17 balance and IL-22 production. | Relevant to IL-22 regulation in inflammation. |
| IL23A | Subunit of IL-23, which promotes IL-22 production by Th17 cells. | Upstream regulator of IL-22 availability. |
| IL1B | Interleukin-1 beta, which can induce IL-22 expression. | Inflammatory mediator affecting IL-22 levels. |
| IL6 | Interleukin-6, which together with TGF-beta promotes Th17 differentiation and IL-22 production. | Context-dependent regulator of IL-22. |
| TGFB1 | Transforming growth factor beta 1, involved in Th17 differentiation and IL-22 regulation. | Modulates IL-22 production in autoimmune settings. |
| AHR | Aryl hydrocarbon receptor, a transcription factor that promotes IL-22 expression. | Regulates IL-22 production in innate lymphoid cells. |
How Is interleukin-22 receptor binding Regulated?
Interleukin-22 receptor binding is regulated at multiple levels. The soluble decoy receptor IL-22BP directly competes with membrane-bound IL-22R1 for IL-22, thereby inhibiting binding and downstream signaling. Expression of IL-22BP is itself regulated by inflammatory stimuli, providing a feedback mechanism to limit IL-22 activity. Additionally, the expression levels of IL-22R1 and IL-10R2 on target cells determine the capacity for binding and signaling. Negative feedback regulators such as SOCS3 can attenuate signaling after receptor activation. Furthermore, the balance between IL-22 and other cytokines, such as IL-17A and IFN-gamma, influences the overall response.
interleukin-22 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL22 | Autoimmune uveitis | Experimental autoimmune uveitis (EAU) mouse model |
| IL22RA1 | Periodontitis | Rat experimental periodontitis model |
| IL22BP | Pneumococcal pneumonia | Mouse model of Streptococcus pneumoniae infection |
| IL22BP | Bleomycin-induced lung injury | Mouse model of bleomycin-induced pulmonary fibrosis |
| IL22RA1 | SARS-CoV-2 infection | Human blood hematopoietic cells from COVID-19 patients |
Interleukin-22 receptor binding in autoimmune and inflammatory diseases
Dysregulated IL-22 receptor binding is implicated in several autoimmune and inflammatory conditions. In experimental autoimmune uveitis, IL-22 and its receptor contribute to the development and pathogenesis of ocular inflammation, with IL-22BP playing a protective role by neutralizing IL-22. In periodontitis, the temporal expression of IL-22, IL-22R1, and IL-22BP correlates with disease progression, suggesting that the balance of these factors influences tissue destruction. Similarly, in allergic airway inflammation, IL-22BP contributes to airway hyperresponsiveness, highlighting the importance of regulating IL-22 binding.
Interleukin-22 receptor binding in infectious diseases
IL-22 receptor binding is critical for host defense against bacterial and viral pathogens. During pneumococcal pneumonia, IL-22BP constrains IL-22 activity, affecting host defense and oxidative phosphorylation genes. In SARS-CoV-2 infection, distinct expression patterns of IL-22R1 on blood hematopoietic cells have been observed, suggesting a role in the immune response to the virus. These findings indicate that modulating IL-22 receptor binding could influence the outcome of infectious diseases.
Interleukin-22 receptor binding in tissue injury and fibrosis
IL-22 receptor binding plays a dual role in tissue repair and fibrosis. In bleomycin-induced lung injury, IL-22BP controls IL-22-driven injury, and its absence exacerbates fibrosis. This suggests that tight regulation of IL-22 binding is necessary to balance protective tissue repair and pathological fibrosis. Understanding these mechanisms could lead to therapies that promote regeneration without inducing fibrosis.
From interleukin-22 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL22RA1 knockout abolish IL-22 signaling? | IL22RA1 knockout cell lines or mice |
| What is the effect of a point mutation in the IL-22 binding interface? | Point-mutation knock-in of IL22 or IL22RA1 |
| Can a tagged IL-22R1 be used to track receptor localization? | Knock-in of a fluorescent or epitope tag at the endogenous IL22RA1 locus |
| What happens when IL-22 is overexpressed in epithelial cells? | Overexpression of IL22 in cell lines or transgenic mice |
| How does IL-22BP deficiency affect inflammation? | IL22BP knockout mice |
| Does IL-22 receptor binding regulate antimicrobial peptide production? | In vitro epithelial cell cultures treated with IL-22 |
How to Study the interleukin-22 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Characterizing IL-22/IL-22R1 interaction |
| Co-immunoprecipitation | Protein-protein interaction | Confirming receptor complex formation |
| Western blot | STAT3 phosphorylation | Assessing downstream signaling |
| qRT-PCR | mRNA expression levels | Quantifying IL22, IL22RA1, IL22BP in tissues |
| Flow cytometry | Cell surface receptor expression | Analyzing IL-22R1 on hematopoietic cells |
| RNA-seq | Transcriptome-wide expression | Identifying IL-22-regulated genes |
| ELISA | Cytokine levels | Measuring IL-22 and IL-22BP in serum or supernatants |
Biochemical binding assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure the affinity and kinetics of IL-22 binding to its receptor. Co-immunoprecipitation and pull-down assays can confirm the interaction in cell lysates. These methods provide quantitative data on binding constants and are essential for characterizing mutants.
Cell-based signaling assays
IL-22 receptor binding can be assessed by measuring downstream signaling events, such as STAT3 phosphorylation using Western blotting or flow cytometry. Reporter gene assays driven by STAT3-responsive elements can quantify transcriptional activation. These assays are useful for screening inhibitors or evaluating receptor variants.
Expression analysis
Quantitative RT-PCR and RNA-seq can measure the expression levels of IL22, IL22RA1, IL10RB, and IL22BP in tissues or cells. This is important for understanding how expression patterns influence binding and signaling in different disease contexts.
Imaging and localization
Fluorescence microscopy and flow cytometry can visualize the localization of IL-22 receptors on the cell surface and track internalization upon ligand binding. Tagged receptors or fluorescently labeled IL-22 can be used to study binding dynamics in live cells.
How CRISPR Can Be Used to Study GO:0045518 interleukin-22 receptor binding
Knockout
CRISPR-Cas9 knockout of IL22RA1 or IL10RB can completely abolish IL-22 receptor binding and downstream signaling, providing a clean background to study the specific contributions of these genes. Knockout of IL22 itself can eliminate ligand availability. These models are valuable for validating the requirement of specific components in IL-22-mediated functions.
Point Mutation
Introducing point mutations in the binding interface of IL-22 or IL-22R1 can fine-tune binding affinity and specificity. For example, mutating residues critical for the IL-22/IL-22R1 interaction can reveal the structural determinants of binding. Such models help dissect the molecular basis of receptor-ligand recognition without completely eliminating the protein.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) at the endogenous IL22RA1 locus allows for real-time tracking of receptor expression and localization. This approach preserves endogenous regulation and provides a tool for imaging binding events in live cells.
Overexpression
Overexpression of IL22 or IL22RA1 in cell lines or transgenic animals can amplify signaling and reveal gain-of-function phenotypes. This is useful for studying the consequences of excessive IL-22 receptor binding in inflammation and tissue repair. However, overexpression may also induce non-physiological effects, so results should be interpreted with caution.
How EDITGENE Supports interleukin-22 receptor binding Research
Researchers studying interleukin-22 receptor binding-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of these genes.
Contact EDITGENE today to design your custom CRISPR model for interleukin-22 receptor binding research.
Frequently Asked Questions About interleukin-22 receptor binding
What is interleukin-22 receptor binding?
Interleukin-22 receptor binding (GO:0045518) is the molecular function of binding to an interleukin-22 receptor, typically involving the cytokine IL-22 and its receptor complex.
What genes are involved in interleukin-22 receptor binding?
Key genes include IL22 (ligand), IL22RA1 and IL10RB (receptor subunits), and IL22BP (decoy receptor).
What is the role of IL-22BP in interleukin-22 receptor binding?
IL-22BP is a soluble decoy receptor that binds IL-22 and prevents it from interacting with the membrane-bound receptor, thereby inhibiting signaling.
How is interleukin-22 receptor binding studied?
Common methods include surface plasmon resonance, co-immunoprecipitation, Western blotting for STAT3 phosphorylation, and CRISPR knockout models.
What diseases are associated with interleukin-22 receptor binding?
It is implicated in autoimmune uveitis, periodontitis, pneumococcal pneumonia, bleomycin-induced lung injury, and SARS-CoV-2 infection.
Can CRISPR be used to study interleukin-22 receptor binding?
Yes, CRISPR knockout of IL22RA1 or IL22 can abolish binding, while point mutations can fine-tune affinity, and knock-in tags allow tracking.
What is the difference between IL-22 and IL-22BP?
IL-22 is the ligand that binds the receptor to initiate signaling, while IL-22BP is a soluble decoy receptor that neutralizes IL-22.
How does interleukin-22 receptor binding affect the immune system?
It regulates epithelial barrier immunity, antimicrobial peptide production, and inflammatory responses, influencing Th1/Th17 balance.
What cell types express the interleukin-22 receptor?
The receptor is primarily expressed on epithelial cells, but expression on hematopoietic cells has also been observed in certain conditions.
What are the therapeutic implications of targeting interleukin-22 receptor binding?
Modulating this interaction could treat inflammatory diseases, infections, and tissue injury, making it a target for drug development.
Conclusion
Interleukin-22 receptor binding (GO:0045518) is a fundamental molecular event that initiates IL-22 signaling, with critical roles in immunity, tissue repair, and disease. The interaction is tightly regulated by the soluble decoy receptor IL-22BP and is implicated in a variety of pathological conditions, from autoimmune uveitis to viral infections. Understanding the structural and functional details of this binding event provides a foundation for developing targeted therapies. Researchers can leverage CRISPR-based tools to dissect the molecular players and their contributions to health and disease.
References
- 1. Lindahl H et al.. 2021. Interleukin-22 Influences the Th1/Th17 Axis.. Front Immunol 12:618110 PMID: 33692792
- 2. Sunami R et al.. 2026. Contribution of Interleukin-22 Binding Protein to the Development of Allergen-Induced Airway Hyperresponsiveness.. Int J Mol Sci 27(13) PMID: 42450179
- 3. Albayrak N et al.. 2022. Distinct Expression Patterns of Interleukin-22 Receptor 1 on Blood Hematopoietic Cells in SARS-CoV-2 Infection.. Front Immunol 13:769839 PMID: 35422799
- 4. Logsdon NJ et al.. 2002. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes.. J Interferon Cytokine Res 22(11):1099-112 PMID: 12513909
- 5. Pan S et al.. 2018. Temporal expression of interleukin-22, interleukin-22 receptor 1 and interleukin-22-binding protein during experimental periodontitis in rats.. J Periodontal Res 53(2):250-257 PMID: 29080226
- 6. Trevejo-Nunez G et al.. 2019. Interleukin-22 (IL-22) Binding Protein Constrains IL-22 Activity, Host Defense, and Oxidative Phosphorylation Genes during Pneumococcal Pneumonia.. Infect Immun 87(11) PMID: 31451621
- 7. Zhang Z et al.. 2024. IL-22 Binding Protein Controls IL-22-Driven Bleomycin-Induced Lung Injury.. Am J Pathol 194(3):338-352 PMID: 38101567
- 8. Kim Y et al.. 2016. The Role of Interleukin-22 and Its Receptor in the Development and Pathogenesis of Experimental Autoimmune Uveitis.. PLoS One 11(5):e0154904 PMID: 27166675
